Product NDC: | 67457-221 |
Proprietary Name: | Methotrexate |
Non Proprietary Name: | Methotrexate |
Active Ingredient(s): | 1 g/40mL & nbsp; Methotrexate |
Administration Route(s): | INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 67457-221 |
Labeler Name: | Mylan Institutional LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA040716 |
Marketing Category: | ANDA |
Start Marketing Date: | 20120627 |
Package NDC: | 67457-221-02 |
Package Description: | 1 VIAL, GLASS in 1 CARTON (67457-221-02) > 2 mL in 1 VIAL, GLASS |
NDC Code | 67457-221-02 |
Proprietary Name | Methotrexate |
Package Description | 1 VIAL, GLASS in 1 CARTON (67457-221-02) > 2 mL in 1 VIAL, GLASS |
Product NDC | 67457-221 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Methotrexate |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS |
Start Marketing Date | 20120627 |
Marketing Category Name | ANDA |
Labeler Name | Mylan Institutional LLC |
Substance Name | METHOTREXATE |
Strength Number | 1 |
Strength Unit | g/40mL |
Pharmaceutical Classes | Folate Analog Metabolic Inhibitor [EPC],Folic Acid Metabolism Inhibitors [MoA] |